Elly Gerald Stoica

Array ( [id] => 17556091 [patent_doc_number] => 11312767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Cross-species anti-latent TGF-beta 1 antibodies [patent_app_type] => utility [patent_app_number] => 17/466509 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 21 [patent_no_of_words] => 35247 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356816 [patent_doc_number] => 20220017612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/465247 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067269 [patent_doc_number] => 20240101695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => IMMUNOGLOBULIN E ANTIBODY COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/043554 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -141 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691022 [patent_doc_number] => 20230321209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => MODIFIED MYCOBACTERIUM BOVIS VACCINES [patent_app_type] => utility [patent_app_number] => 18/043923 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685905 [patent_doc_number] => 20220193197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 17/407011 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17407011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20149234 [patent_doc_number] => 20250249072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/042068 [patent_app_country] => US [patent_app_date] => 2021-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18384510 [patent_doc_number] => 11655282 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Chimeric engulfment receptor molecules [patent_app_type] => utility [patent_app_number] => 17/400082 [patent_app_country] => US [patent_app_date] => 2021-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 161 [patent_figures_cnt] => 218 [patent_no_of_words] => 50052 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770887 [patent_doc_number] => 20230365690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => METHODS OF TREATING MALIGNANT GLIOBLASTOMA [patent_app_type] => utility [patent_app_number] => 18/040888 [patent_app_country] => US [patent_app_date] => 2021-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412768 [patent_doc_number] => 20220047672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => COMPOSITIONS AND METHODS INVOLVING LAYILIN [patent_app_type] => utility [patent_app_number] => 17/396475 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17396475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342203 [patent_doc_number] => 20220008534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => Combination Of Local And Systemic Immunomodulative Therapies For Enhanced Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/382943 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213160 [patent_doc_number] => 20210346496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/382446 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17229921 [patent_doc_number] => 20210356478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => METHOD, ARRAY AND USE FOR DETERMINING THE PRESENCE OF PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 17/382613 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17382613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355374 [patent_doc_number] => 20220016170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES [patent_app_type] => utility [patent_app_number] => 17/381587 [patent_app_country] => US [patent_app_date] => 2021-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214539 [patent_doc_number] => 20210347876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => THERAPIES FOR TREATING INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 17/379679 [patent_app_country] => US [patent_app_date] => 2021-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369982 [patent_doc_number] => 20220025034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/378629 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200147 [patent_doc_number] => 20210340242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS FOR TREATING OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/378618 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355416 [patent_doc_number] => 20220016212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS OF TREATING CHEMOTHERAPY INDUCED NEUTROPENIA USING FIXED DOSES OF G-CSF PROTEIN COMPLEX [patent_app_type] => utility [patent_app_number] => 17/374302 [patent_app_country] => US [patent_app_date] => 2021-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15161 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17374302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19948391 [patent_doc_number] => 12319738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-03 [patent_title] => Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer [patent_app_type] => utility [patent_app_number] => 17/366580 [patent_app_country] => US [patent_app_date] => 2021-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 45671 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17366580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18101255 [patent_doc_number] => 11541126 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-03 [patent_title] => Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof [patent_app_type] => utility [patent_app_number] => 17/365959 [patent_app_country] => US [patent_app_date] => 2021-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 109518 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17365959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126241 [patent_doc_number] => 20210301009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => INHIBITING GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR (GM-CSF) PREVENTS PRETERM BIRTH [patent_app_type] => utility [patent_app_number] => 17/346928 [patent_app_country] => US [patent_app_date] => 2021-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346928 [rel_patent_id] =>[rel_patent_doc_number] =>)